Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ciphergen Biosystems(CIPH): -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (35)	3/9/2002 1:24:31 PM
From: nigel bates	Read Replies (1) \| Respond to of 510

Very interesting. <g> Meanwhile - Ciphergen Adopts Stockholder Rights Plan FREMONT, Calif., March 8 /PRNewswire-FirstCall/ -- Ciphergen Biosystems, Inc. (Nasdaq: CIPH - news) announced today that its Board of Directors has approved the adoption of a Share Purchase Rights Plan. The Rights Plan is designed to assure that Ciphergen stockholders receive fair and equal treatment in the event of any proposed takeover of the company and to guard against partial tender offers and other abusive tactics to gain control of the company without paying all stockholders the fair value of their shares. The plan was not adopted in response to any specific attempt to acquire the company. Similar to Rights Plans adopted by many other companies, Ciphergen will issue a non-taxable dividend of one right for each share of its Common Stock held by stockholders of record as of the close of business on March 31, 2002. Each right will initially entitle stockholders to purchase a fractional share of Ciphergen's Preferred Stock for $50. However, the rights are not immediately exercisable and will become exercisable only upon the occurrence of certain events. If a person or group acquires, or announces a tender or exchange offer that would result in the acquisition of 15 percent or more of Ciphergen Common Stock while the Rights Plan remains in place, then, unless the rights are redeemed by Ciphergen for $0.001 per right, the rights will become exercisable by all rights holders, except the acquiring person or group, for shares of Ciphergen or the third party acquirer having a value of twice the right's then-current exercise price. Further details of the plan are outlined in a letter that will be mailed to stockholders as of the record date. About Ciphergen Ciphergen develops, manufactures and markets a family of ProteinChip® Systems for clinical, research and process proteomics applications, as well as a broad range of bioseparations media for protein purification through its BioSepra process chromatography division. ProteinChip Systems enable protein discovery, profiling, characterization and assay development to provide researchers with predictive analysis capabilities and a better understanding of biological functions at the protein level. ProteinChip Systems are enabling tools in the emerging field of protein-based biology research, known as proteomics. Proteomics provides a direct approach to understanding the role of proteins in the biology of disease, monitoring disease progression and evaluating the therapeutic effects and side effects of drugs. Ciphergen believes proteomics will be a major focus of biological research by enhancing the understanding of gene function and the molecular basis of disease...

To: tuck who wrote (35)	4/4/2002 9:17:58 AM
From: nigel bates	Read Replies (1) \| Respond to of 510

FREMONT, Calif., April 4 /PRNewswire-FirstCall/ -- Ciphergen Biosystems, Inc. (Nasdaq: CIPH - news) today announced that more than two dozen studies involving its proprietary SELDI ProteinChip® Technology for the early detection of many different cancers will be presented during the American Association for Cancer Research (AACR) 93rd meeting in San Francisco, April 7-10. By using Ciphergen's SELDI ProteinChip Technology, these studies have identified multiple biomarkers and biomarker patterns that reveal protein expression associated with the early detection of cancer. Leading clinical researchers from around the world will present at AACR data generated using ProteinChip Systems that show impressive rates of cancer detection including sensitivities (true positives) ranging from 68-100% and specificities (true negatives)ranging from 81-96%. Users of SELDI ProteinChip Technology who will be presenting this week include Johns Hopkins University, M.D. Anderson Cancer Center, Mt. Sinai School of Medicine, Eastern Virginia Medical School, Lawrence Livermore National Laboratory, FDA, NCI, Brigham & Women's Hospital, Moffitt Cancer Center and others. Highlights of selected papers to be presented at AACR include: Cancer Study Sensitivity Specificity Institution Ovarian 94-100% 96% NCI, FDA, Northwestern Prostate 93.3% 93.8% Eastern Virginia Medical School Breast 92% 82% Johns Hopkins Medical School Liver 92.5% 90% Chinese University of Hong Kong Bladder 79% 81% Eastern Virginia Medical School ``We are very excited about the results coming out of leading medical research centers, both from their internal research programs and through their collaborations with Ciphergen scientists,'' said William Rich, Ph.D., President and CEO of Ciphergen. ``The 25 abstracts being presented at the AACR this year underscore the progress our customers are making in the area of early detection of cancer, and at the same time further validate Ciphergen's proprietary SELDI ProteinChip platform as the leading technology for biomarker discovery and pattern research.'' Dr. George L. Wright, who leads the cancer research effort at Eastern Virginia Medical School and is a Principal Investigator in the Early Detection Research Network funded by the National Cancer Institute, added, ``As researchers continue to unravel the complexities of disease processes, it has become increasingly apparent that future diagnostics will go beyond correlating a single protein to a disease, and instead will look at characteristic protein patterns to diagnose and infer disease progression. Ciphergen's technology offers researchers an extremely promising approach to detect the early onset of cancer.'' When compared to a single biomarker, multiple biomarkers offer significantly increased statistical power and superior predictive value for greater utility in diagnosis, toxicology, patient stratification and patient monitoring. Until recently, scientists lacked the tools to rapidly produce large sets of multiple-protein expression data for comparative analysis. With the recent release of Ciphergen's ProteinChip Biomarker System, clinical researchers are now collecting reproducible protein expression data on hundreds of proteins at once -- opening the door to rapid, simplified multiple pattern analysis. For large-scale and time-sensitive projects, collaborations with Ciphergen's state-of-the-art Biomarker Centers(TM) are helping cancer researchers significantly speed-up differential protein expression, protein characterization and ID, assay development and clinical validation. In order to better serve our collaborators in North America and Europe, Ciphergen has established, equipped and staffed Biomarker Centers in Fremont, CA, Malvern, PA and Copenhagen, Denmark...